A PROSPECTIVE OBSERVATIONAL STUDY ON SAFETY AND EFFICACY OF HYDROXYCHLOROQUINE AGAINST DICLOFENAC IN OSTEOARTHRITIS

Praveen D; Rujaswini, T; Elancheziyan K

doi:10.22159/ajpcr.2018.v11s4.31688

Authors

Praveen D Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, Tamil Nadu, India.
Rujaswini, T Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, Tamil Nadu, India.
Elancheziyan K 3Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11s4.31688

Keywords:

Osteoarthritis, Hydroxychloroquine, Diclofenac

Abstract

Objective: The main aim of this study is to compare the effectiveness of treatment of osteoarthritis (OA) with hydroxychloroquine against diclofenac and to compare the safety of the treatment of OA with hydroxychloroquine against diclofenac. The secondary objectives are the comparison of onset and duration of action of both the treatments.

Methods: A prospective interventional study has been done in a tertiary care teaching hospital for 1 year from January 2016 to December 2016. The interventional model included an active control (diclofenac - nonsteroidal anti-inflammatory drugs). The control group received diclofenac 75 mg for 12 weeks, whereas the test group received hydroxychloroquine 200 mg for 3 months.

Results: Pain control is significantly rapid in diclofenac group, whereas the duration of action is significantly increased in hydroxychloroquine. It can be clearly seen that the hydroxychloroquine group significantly increases the quality of life when compared to diclofenac group. It is clearly seen that the incidence of gastric ulcers is more common in diclofenac group when compared to hydroxychloroquine group.

Conclusion: Hydroxychloroquine offers a newer spectrum in the management of OA. Although it is slow acting, it has significantly increased the quality of patient as it can have a prolonged action. Hence, hydroxychloroquine can be used as a newer entity in the management of OA.

Downloads

Download data is not yet available.

References

Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB, et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43:4-13.

Lanas A. Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: A trip from peptic ulcer to colon cancer. Am J Med Sci 2009;338:96-106.

MassÃ³ GonzÃ¡lez EL, Patrignani P, Tacconelli S, GarcÃa RodrÃguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010;62:1592-601.

Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437.

FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.

Hochberg MC. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin Arthritis Rheum 2002;32:4-14.

Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1-5.

Robertson CR, Rice JR, Allen NB: Treatment of erosive osteoarthritis with hydroxchloroquine. Arthritis Rheum 1993;36(Suppl):S167.

Bryant LR, des Rosier KF, Carpenter MT. Hydroxychloroquine in the treatment of erosive osteoarthritis. J Rheumatol 1995;22:1527-31.

Punzi L, Bertazzolo N, Pianon M, Michelotto M, Todesco S. Soluble interleukin 2 receptors and treatment with hydroxychloroquine in erosive osteoarthritis. J Rheumatol 1996;23:1477-8.

Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W, et al. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 1998;274:R1058-64.

Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000;165:1534-40.